{"filing":{"accession_number":"0001140361-26-031028","cik":"0000320017","ticker":"LSTA","company_name":"LISATA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-03","primary_document":"ef20079399_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm"},"events":[{"id":23496,"run_id":21242,"accession_number":"0001140361-26-031028","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The Company's Board approved a 72% workforce reduction effective August 3, 2026, with estimated severance and termination costs of approximately $1.2 million through Q3 2026.","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23736,"accession_number":"0001140361-26-031028","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure explicitly describes a 72% workforce reduction approved by the board on August 3, 2026, effective immediately, with estimated severance and termination costs of approximately $1.2 million through Q3 2026. This is a classic workforce_reduction event under Item 2.05, combining both the operational decision and the associated exit costs. The magnitude (72% reduction) and quantified charges make this material to investors assessing the company's cost structure and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:07:41.982496+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":23497,"run_id":21242,"accession_number":"0001140361-26-031028","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Dr. Kristen K. Buck, Executive Vice President of R\u0026D and Chief Medical Officer, was terminated effective August 3, 2026 in connection with the Board-approved workforce reduction, triggering contractual severance obligations including 12 months base salary and target bonus plus COBRA.","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23737,"accession_number":"0001140361-26-031028","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The primary disclosed action is the termination of Dr. Kristen K. Buck, Executive Vice President of R\u0026D and Chief Medical Officer, effective August 3, 2026, in connection with a Board-approved workforce reduction. While the section also mentions a retention bonus to another executive, the material event centers on the departure of a named executive officer in a senior R\u0026D/medical leadership role, triggering contractual severance obligations (12 months base salary and target bonus plus COBRA). The secondary compensation arrangement is ancillary to the principal departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:07:41.982496+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":23498,"run_id":21242,"accession_number":"0001140361-26-031028","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"The Company filed a lawsuit in Delaware Court of Chancery against Kuva Labs and its subsidiary alleging breach of a Merger Agreement dated March 6, 2026, and seeking damages for stockholder benefits.","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23738,"accession_number":"0001140361-26-031028","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The Company filed a lawsuit in Delaware Court of Chancery against Kuva Labs and its subsidiary alleging breach of a Merger Agreement dated March 6, 2026, and seeking damages for stockholder benefits. This is a material litigation disclosure under Item 8.01 involving a significant M\u0026A transaction dispute that would affect investor assessment of the deal's status and potential recovery.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:07:41.982496+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23736,"accession_number":"0001140361-26-031028","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure explicitly describes a 72% workforce reduction approved by the board on August 3, 2026, effective immediately, with estimated severance and termination costs of approximately $1.2 million through Q3 2026. This is a classic workforce_reduction event under Item 2.05, combining both the operational decision and the associated exit costs. The magnitude (72% reduction) and quantified charges make this material to investors assessing the company's cost structure and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:07:41.982496+00:00","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-08-04"},{"id":23737,"accession_number":"0001140361-26-031028","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The primary disclosed action is the termination of Dr. Kristen K. Buck, Executive Vice President of R\u0026D and Chief Medical Officer, effective August 3, 2026, in connection with a Board-approved workforce reduction. While the section also mentions a retention bonus to another executive, the material event centers on the departure of a named executive officer in a senior R\u0026D/medical leadership role, triggering contractual severance obligations (12 months base salary and target bonus plus COBRA). The secondary compensation arrangement is ancillary to the principal departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:07:41.982496+00:00","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-08-04"},{"id":23738,"accession_number":"0001140361-26-031028","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The Company filed a lawsuit in Delaware Court of Chancery against Kuva Labs and its subsidiary alleging breach of a Merger Agreement dated March 6, 2026, and seeking damages for stockholder benefits. This is a material litigation disclosure under Item 8.01 involving a significant M\u0026A transaction dispute that would affect investor assessment of the deal's status and potential recovery.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:07:41.982496+00:00","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-08-04"}]}